Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:1.10.3.1 (tyrosinase)
 9,065 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Oxygen free radical (OFR)-mediated oxidative stress in myocardial cells following ischemia could damage unit membrane and macromolecules such as nucleic acids (DNA). It is being reported that under this condition these cells produce antioxidants and heat shock proteins (HSP 70). It is implied that this family of proteins could function as a "molecular chaperone" in the cell and hence has to be transported to various target sites. This process is comparable to the induction of oxygen free radicals in melanocytes and its response, melanin production following UV light exposure stress. Lamp-1, trp-1 and tyrosinase are melanosomal-associated stress relief proteins which are involved in the production of melanin in the subcellular organelle, melanosomes. UV exposure studies as well as gene transfection studies and antisense hybridization in human melanoma cells clearly indicated an increase and marked coordinated interaction of all these stress relief proteins in melanogenesis. These proteins are synthesized in the endoplasmic reticulum and have to undergo posttranslation modification, sorting and posting to their respective target sites. We simultaneously identified and characterized an ER resident protein, calnexin. It became the potential candidate for "chaperoning" these proteins following translation. Based on the computer analysis of HSP 70 cDNA, we postulate that similar to stress response proteins in melanogenesis, stress relief proteins in myocardial cells may also be modulated by the same ER resident protein, calnexin.
 ...
PMID:Stress relief protein modulation by calnexin. 890 96

Dopamine can form reactive oxygen species and other reactive metabolites that can modify proteins and other cellular constituents. In this study, we tested the effect of dopamine oxidation products, other generators of reactive oxygen species, and a sulfhydryl modifier on the function of glutamate transporter proteins. We also compared any effects with those on the dopamine transporter, a protein whose function we had previously shown to be inhibited by dopamine oxidation. Preincubation with the generators of reactive oxygen species, ascorbate (0.85 mM) or xanthine (500 microM) plus xanthine oxidase (25 mU/ml), inhibited the uptake of [3H]glutamate (10 microM) into rat striatal synaptosomes (-54 and -74%, respectively). The sulfhydryl-modifying agent N-ethylmaleimide (50-500 microM) also led to a dose-dependent inhibition of [3H]glutamate uptake. Preincubation with dopamine (100 microM) under oxidizing conditions inhibited [3H]glutamate uptake by 25%. Exposure of synaptosomes to increasing amounts of dopamine quinone by enzymatically oxidizing dopamine with tyrosinase (2-50 U/ml) further inhibited [3H]glutamate uptake, an effect prevented by the addition of glutathione. The effects of free radical generators and dopamine oxidation on [3H]glutamate uptake were similar to the effects on [3H]dopamine uptake (250 nM). Our findings suggest that reactive oxygen species and dopamine oxidation products can modify glutamate transport function, which may have implications for neurodegenerative processes such as ischemia, methamphetamine-induced toxicity, and Parkinson's disease.
 ...
PMID:Inhibition of glutamate transport in synaptosomes by dopamine oxidation and reactive oxygen species. 928 42

Cardiotoxicity associated with cancer treatment is an important field of interest especially as the new class of VEGF signaling pathway inhibitors (VSP) continues to grow. Small molecule tyrosine kinase inhibitors such as sorafenib, sunitinib, and pazopanib inhibit the downstream pathways of all three of the vascular endothelial growth factor receptors (VEGFR 1, 2, and 3). Other targets of these agents include kinases involved in vascular and myocardial homoeostasis. These agents are all known to frequently cause hypertension, their most common side-effect. Myocardial ischemia has also been reported, but the frequency and etiology of VSP-related ischemia is poorly characterized. This manuscript describes the first reported case of sorafenib-associated multivessel coronary vasospasm in a 57-year-old patient with hepatocellular carcinoma. He underwent sorafenib treatment, a tyrosinase inhibitor, 400 mg twice a day. The vasospasm was reversible under nitroglycerin. Possible mechanisms are also discussed.
 ...
PMID:Sorafenib-associated multivessel coronary artery vasospasm. 2158 15